Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IMMURON (IMRN : NSDQ)
 
 • Company Description   
Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale, Australia.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.78 Daily Weekly Monthly
20 Day Moving Average: 6,665 shares
Shares Outstanding: 5.70 (millions)
Market Capitalization: $15.83 (millions)
Beta: 1.73
52 Week High: $5.20
52 Week Low: $2.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.02% -0.92%
12 Week -3.81% 5.74%
Year To Date 11.20% 28.26%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
62 LYGON STREET LEVEL 3
-
CARLTON,C3 3053
AUS
ph: 610398245254
fax: 6103 98227735
dave@redchip.com http://www.immuron.com.au
 
 • General Corporate Information   
Officers
Jerry Kanellos - Chief Executive Officer
Roger Aston - Chairman
Phillip Hains - Chief Financial Officer
Daniel Pollock - Director
Stephen Anastasiou - Director

Peer Information
IMMURON (CORR.)
IMMURON (RSPI)
IMMURON (CGXP)
IMMURON (BGEN)
IMMURON (GTBP)
IMMURON (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45254U101
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 5.70
Most Recent Split Date: (:1)
Beta: 1.73
Market Capitalization: $15.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.90
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 23.77
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 23.65
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 3.09
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©